<div class="fultxt">
											  <ol>
											  <li>Chen G, Wu D, Guo W, Cao Y, Huang D, et al. (2020) Clinical and immunologic features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-9.</li>
											  <li>Tang N, Bai H, Chen X, Gong J, Li D, et al. (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18: 1094-9.</li>
											  <li>Chen N, Zhou M, Dong X, Qu J, Gong F, et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507-13.</li>
											  <li>Guan WJ, Ni ZY, Hu Y, Liang Wh, Ou Cq, et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. New England J Med 382: 1708-20.</li>
											  <li>Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506.</li>
											  <li>Iba T, Levy JH (2019) Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost 17: 283-94.</li>
											  <li>Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, et al. (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-10.</li>
											  <li>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, et al. (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395: 1417-8.</li>
											  <li>Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76: 455-66.</li>
											  </ol>
											  </div>